Resonac Announces Nomination of Outside Board Director Candidates

November 26, 2024
Resonac Holdings Corporation

Resonac Holdings Corporation (President: Hidehito Takahashi, hereinafter “Resonac”) is pleased to announce the decision made at the Board of Directors’ Meeting held on November 26, 2024, to nominate Mr. Masaru Onishi and Ms. Izumi Sakakibara as candidates for outside board directors. This decision is subject to approval at the 116th Annual General Meeting of Shareholders scheduled for late March 2025.
 

Mr. Onishi joined Japan Airlines Co., Ltd. (hereinafter “Japan Airlines”) and built his career in both the maintenance and planning sectors. In 2009, he was appointed as President of Japan Air Commuter Co., Ltd. Subsequently, in 2010, he became President of Japan Airlines, where he led the company through its corporate rehabilitation under the Corporate Reorganization Act. Under his leadership, Japan Airlines successfully relisted on the stock exchange in just 2 years and 8 months. Thus, Mr. Onishi contributed to the resurgence of the new Japan Airlines. Even after stepping down as Chairman of the Board of Japan Airlines, Mr. Onishi has served as an outside board director in various industries, bringing with him a wealth of experience and accomplishments as an executive. Additionally, he possesses deep knowledge of safety, which Resonac prioritizes, and has a prominent level of insight, ethical standards, and fair judgment necessary for enhancing corporate value. Therefore, Resonac decided to nominate Mr. Onishi as a candidate for Outside Board Director.

Ms. Sakakibara contributed to the establishment of heart transplant systems at the former Ministry of Health and Welfare (now the Ministry of Health, Labour and Welfare). At Toray Industries, Inc., she participated in the pharmacology and clinical development of anti-inflammatory and immunosuppressive agents and contributed to licensing activities. Later, at Otsuka Group, she dedicated herself to expanding the infusion business overseas and promoting regenerative medicine projects. Ms. Sakakibara has extensive experience and expertise in the fields of pharmaceuticals and regenerative medicine. Since joining FUJIFILM Corporation in 2017, she has demonstrated strategic insight and strong drive in business development, portfolio restructuring, and CVC (corporate venture capital) investments both domestically and internationally, achieving significant results. We expect that her broad perspective and insights, based on her diverse experiences, will provide valuable input to Resonac. Therefore, Resonac decided to nominate Ms. Sakakibara as a candidate for Outside Board Director.

With the participation of Mr. Onishi and Ms. Sakakibara in the management team, Resonac will leverage their extensive experience and expertise to further enhance its corporate value and strengthen its management structure.